Regeneron Pharmaceuticals (REGN) Liabilities and Shareholders Equity (2009 - 2026)

Regeneron Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $41.7 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 9.19% year-over-year to $41.7 billion; the TTM figure through Jun 2026 stood at $163.3 billion (up 8.19% YoY), while the FY2025 annual figure was $40.6 billion, up 7.41% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $41.7 billion, up from $40.9 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $41.7 billion in Q2 2026, with the low at $26.3 billion in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $35.2 billion (2024), against an average of $34.5 billion.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 48.26% in 2022, then climbed 5.91% in 2025.
• Regeneron Pharmaceuticals' Liabilities and Shareholders Equity stood at $29.2 billion in 2022, then grew by 13.23% to $33.1 billion in 2023, then increased by 14.15% to $37.8 billion in 2024, then advanced by 7.41% to $40.6 billion in 2025, then gained by 2.89% to $41.7 billion in 2026.
• Business Quant data shows REGN's Liabilities and Shareholders Equity at $41.7 billion in Q2 2026, $40.9 billion in Q1 2026, and $40.6 billion in Q4 2025.